BRAF and malignant glioma: In a study involving the combination of dabrafenib and trametinib for recurrent or refractory high-grade gliomas (HGG) with the BRAF V600E mutation, an objective response was observed in 32% of GBM patients, with a complete response in 6.5% of cases (55).